Oncology
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Automated Report-Derived Oncology VQA Benchmark for Evaluating Vision-Language Models on 3D Medical Imaging
arXiv:2606.02809v1 Announce Type: new Abstract: Evaluating vision-language models (VLMs) on medical images requires benchmarks that are clinically grounded, scalable, and controlled for evaluation confounds. Existing public benchmarks are limited in scale, manually annotated, or potentially leaked into VLM pretraining corpora. We present an automated agent-driven pipeline that generates multiple-choice VQA datasets directly from paired private radiology reports and 3D oncology imaging,...
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...
Organoid-based colorectal tumor microenvironment model for immuno-oncology research
The development of cancer immunotherapies is hindered by the lack of human-relevant models that accurately translate to patient outcomes. We combine patient-derived colorectal tumor organoids (PDOs) and cancer-associated fibroblasts (CAFs) into floating extracellular matrix drops to form miniature colorectal tumors. These SHaking Organoid COcultures (SHOCOs) maintain immune cells in numbers, states and functional interactions that are more physiologically accurate than traditional PDO-based...
Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
HOPE: Interpretable Histology Analysis with Spatial Omics-Derived Signatures for Precision Oncology
Hematoxylin and eosin (H&E) stained images are fundamental clinical tools for disease assessment. However, even with advanced computational models, their prognostic capabilities remain limited. Spatial omics characterizes tumor microenvironments (TME) in detail yet remains clinically inaccessible due to cost and complexity.
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnosesA blood test for more than 50 types of cancer that was billed as the holy grail of oncology has failed to achieve its main objective in a major clinical trial, according to data presented at the world’s largest cancer conference. The goal of the study involving 142,000 NHS patients in the UK was to assess whether adding the multi-cancer early detection test Galleri to standard...
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnosesA blood test for more than 50 types of cancer that was billed as the holy grail of oncology has failed to achieve its main objective in a major clinical trial, according to data presented at the world’s largest cancer conference. The goal of the study involving 142,000 NHS patients in the UK was to assess whether adding the multi-cancer early detection test Galleri to standard...
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnosesA blood test for more than 50 types of cancer that was billed as the holy grail of oncology has failed to achieve its main objective in a major clinical trial, according to data presented at the world’s largest cancer conference. The goal of the study involving 142,000 NHS patients in the UK was to assess whether adding the multi-cancer early detection test Galleri to standard...
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development. And Lilly, now the world's largest pharmaceutical company, is hungrier than ever for deals.